Fig. 3.
NK cell IFNAR1 is required for effective immunotherapeutic control of tumorigenesis using a systemic IFN-inducing agent. IFNα production (IU/ml) by EO771.LMB cells (a) ± 24 h of poly I:C (10 μg/ml) treatment, as measured by ELISA (n = 4/group). Flow cytometry analysis of EO771.LMB cell b H2-Kb and c NK-cell ligands (CD155, KLRG1, H60, Rae-1) ± 24 h of poly I:C (10 μg/ml) treatment (n = 3/group). d Primary tumor weight (mg) at day 16 following IMFP injection of EO771.LMB and thrice weekly treatment of poly I:C (25 μg delivered IP) in WT (n = 7 saline; n = 7 poly I:C) mice. Flow cytometric analysis of PB e NK (NK1.1+) cells, f NKG2D+ NK cells and g CD69+ NK cells at day 12, expressed as frequency (%). h Primary tumor weight (mg) at day 16 following IMFP injection of EO771.LMB and thrice weekly treatment of poly I:C (25 μg delivered IP) in Ifnar−/−NKp46 mice (n = 8 saline; n = 6 poly I:C). Flow cytometric analysis of PB i NK (NK1.1+) cells, j NKG2D+ NK cells and k CD69+ NK cells at day 12, expressed as frequency (%). p values ** < 0.005, *** < 0.0005. **** < 0.0001 determined by Student’s t test. Errors bars, SEM